A recent study has shown that losartan, an AT 1 -receptor antagonist, interacts with thromboxane A 2 (TxA 2 )/prostaglandin H 2 (PGH 2 ) receptors in human platelets. The aim of the present study was to analyse the ability of different angiotensin II (Ang II) AT 1 -receptor antagonists to inhibit TxA 2 -dependent human platelet activation. Platelets were obtained from healthy volunteers and were stimulated with the thromboxane A 2 analogue, U46619 (10 -6 mol/L). U46619-stimulated platelet activation was significantly reduced by losartan in a dose-dependent manner. Only maximal doses of valsartan (5x10 -6 mol/L), reduced U46619-induced platelet activation. The active form of candesartan cilexetil, candesartan (CV-11974), failed to modify platelet activation. Losartan reduced the binding of [ 3 H]-U46619 to platelets, an effect that was observed to a lesser extent with valsartan but not with CV-11974. These results suggest that, whilst some AT 1 -receptor antagonists reduce TxA 2 -dependent human platelet activation, it is not a feature common to all AT 1 antagonists.
Introduction
The peptide angiotensin II (Ang II) plays an important role in cardiac and vascular disorders. Ang II AT 1 -receptor stimulation has been associated with most of the known biological effects of Ang II. In 1982, Furukawa et al. 1 described a new class of chemical compound, 1-benzylimidazole-5 acetic acid, which antagonised the effects of Ang IIinduced contraction. In 1990, the compound N-(biphenylyl-methyl) imidazole (losartan) was described as the first nonpeptide AT 1 -receptor antagonist (AIIA) with high specific affinity for type-1 receptors and it became the prototype of a new therapeutic class of antihypertensive drugs. 2, 3 At present, Ang II AT 1 -receptor antagonists represent a new alternative therapeutic approach to hypertension treatment with the expectation of a lower incidence of adverse events than seen with angiotensin-converting enzyme inhibitors. 4 Thromboxane A 2 (TXA 2 ) acts as an amplifying signal for several agonists of platelet activation,being synthesised and released in response to a variety of agonists,including adenosine diphosphate (ADP). 5 Li et al. have recently demonstrated that losartan antagonised TxA 2 /prostaglandin H 2 (PGH 2 ) receptors in isolated canine coronary arteries. 6 This was supported by a study showing that losartan dose-dependently reduced TxA 2 -receptor-mediated pulmonary hypertension. 7 A recent study from our laboratory has shown that losartan interacts with TXA 2 /PGH 2 receptors in human platelets, 8 an effect that was not observed with the angiotensin-converting enzyme inhibitor, captopril. 8 In the light of this new information concerning the interaction of losartan with TxA 2 /PGH 2 receptors and its antiplatelet effects,the aim of the present study was to analyse the ability of different AIIAs to inhibit TxA 2 -dependent human platelet activation.
Methods

Platelet-rich plasma and platelet aggregation
Platelet-rich plasma (PRP) was isolated from whole peripheral blood of healthy men (age 26-40 years). The protocol was approved by the Institutional Ethics Committee. Volunteer blood donors had received no medication for at least 20 days before the experiments. The blood was collected in 10% (v/v) acid-citrate-dextrose and centrifuged at 1000 rpm for 10 minutes. PRP was collected and the platelet number was adjusted with platelet-poor plasma, obtained from the same donor, to a concentration of 2.5x10 8 cells/mL plasma. As previously reported, 9, 10 platelet activation was evaluated in a lumiaggregometer (two-channel Aggregocorder; Chrono-Log Corporation Hovertown, Pennsylvania, USA) by the change in light transmission. A platelet-poor sample was used as control for 100% light transmission.
PRP (500 µl) was incubated at 37ºC for three minutes in the aggregometer with continuous stirring (1000 rpm) and then stimulated with the TXA 2 agonist, U46619 (10 -6 mol/L), or ADP (10 -5 mol/L).
To standardise the measurements, only the values of turbidimetry at six minutes were used for the calculations. This time period corresponds to the plateau of the maximum value of the first wave of platelet aggregation. This primary wave represents platelet activation rather than aggregation and is partially reversible.The different AIIAs were added to the platelet suspension five minutes before platelets were stimulated with the agonists.
In all cases, the comparative measurements were done in the presence of 0.8% sodium bicarbonate, the solvent in which the drugs were dissolved. 11 PRP was incubated with 1 mmol/L acetylsalicylic acid for at least 30 minutes at 37ºC to inhibit endogenous TXA 2 formation. Platelets were then centrifuged at 1100 rpm for 10 minutes and resuspended in HEPES/Tyrode's buffer (134 mmol/L NaCl, 12 mmol/L NaHCO 3 , 2.9 mmol/L KCl, 0.34 mmol/L Na 2 HPO 4 , 1 mmol/L MgCl 2 , 10 mmol/L HEPES, 5 mmol/L dextrose, and 0.3% BSA, pH 7.4) at a final concentration of 3x10 8 platelets/mL. As reported, 8 aliquots of platelet suspension were incubated with 4 nmol/L [ 3 H]-U46619 in the presence and in the absence of increasing concentrations of the different Ang II AT 1 -receptor antagonists for 30 minutes at 37ºC. It has been previously reported that the binding site of [ 3 H]-U46619 to platelets was saturable at 750 mmol/L. 11 Specific binding was ensured by using incubations containing a 1000-fold excess of unlabeled U46619. The reaction was stopped by centrifugation at 2500 rpm for 10 minutes at 4ºC. The pellet was washed twice and then transferred to a scintillation vial. Duplicate samples were counted in a liquid scintillation counter (Beckman Instruments Inc, Fullerton, CA).
Statistical methods
Results are expressed as mean ± SEM. Unless otherwise stated, each value corresponds to a minimum of six different experiments. To determine the statistical significance of our results, we performed ANOVA with Bonferroni's correction of multiple comparisons or Student's t-test (paired or unpaired).A p-value <0.05 was considered statistically significant.
Results
Effect of AT 1 -receptor antagonists on TxA 2 -activated platelets
Upon activation of platelets with the TXA 2 agonist U46619 (10 -6 mol/L), a 72±4% light transmission was observed. As we previously reported, 8 losartan reduced U46619-induced platelet activation in a concentration-dependent manner (Figure 1a ). The data shown in Figure 1a was obtained six minutes after the stimulus and represent maximal platelet activation. A reduction of U46619-induced platelet activation was also observed in the presence of valsartan ( Figure 1b ). However, only the maximum dose of valsartan (5x10 -5 mol/L) achieved a significant reduction of U46619-stimulated platelet activation (Figure 1b) .
By contrast, the active form of candesartan cilexetil, CV-11974, failed to modify U46619induced platelet activation (Figure 1c ).
Spontaneous platelet activation (<5% light transmission) was not changed by the incubation of the platelet-rich plasma with any of the AT-1type receptor antagonists (% light transmission: losartan: 3±2; valsartan: 3±1; CV-11974: 3±2; NS).
Effect of AT 1 -receptor antagonists on ADP-induced platelet activation
We determined the effect of the different Ang II AT 1 -receptor antagonists on a platelet activation by ADP, (10 -5 mol/L) which is partly dependent on TxA 2 . ADP induced a 62±3% light transmission. An inhibitory effect of 32±3% was observed with 3x10 -3 mol/L aspirin. No additional effect on ADPrelated activation was obtained with aspirin concentrations greater than 3x10 -3 mol/L (data not shown).
Losartan (5x10 -5 mol/L) reduced ADP-induced platelet activation to a similar degree to aspirin (Table 1) . Moreover, no further inhibitory effects on ADP-stimulated platelet activation were observed by adding aspirin to losartan.
Valsartan slightly reduced ADP-induced platelet activation ( Table 1) .
The presence of aspirin increased the inhibito-ry effects of either valsartan and CV-11974 on ADP-stimulated platelet activation ( Table 1) .
Interaction of AT 1 -receptor antagonists with TxA 2 -receptors in human platelets
Losartan competed with radiolabelled U46619 and showed 50% binding inhibition at 7x10 -7 ( Figure 2 ). Valsartan inhibited the binding of [ 3 H]-U46619 to human platelets (Figure 2 ), although this effect was only obtained at a dose of 5x10 -5 mol/L. Lower doses of valsartan (5x10 -6 mol/L) tended to diminish the binding of [ 3 H]-U46619 to human platelets but did not reach statistical significance ( Figure 2 ). No dose of CV-11974 modified the binding of [ 3 H]-U46619 to human platelets. It is noteworthy that the present experimental design does not allow us to exclude the possibility that the interaction of [ 3 H]-U46619 with platelets could include binding to a membrane receptor as well as a certain amount of [ 3 H]-U46619 uptake.
Discussion
The present results provide new evidence of the anti-aggregating effects of some AT 1 -receptor antagonists. Our findings support the hypothesis that some AT 1 -receptor antagonists, particularly losartan, could act as antiplatelet-activating agents by blocking TxA 2 -receptors. Li et al. showed that losartan inhibited TxA 2induced vasoconstriction of canine coronary arteries. 6 Furthermore, it has also been reported that losartan reduced the pulmonary hypertension induced by the TxA 2 agonist U46619 and acted as a competitive antagonist of TxA 2 -receptors in endothelium-denuded rat aortic rings. 7, 12 Moreover, we recently demonstrated that losartan reduced TxA 2 -induced platelet activation by competing with its platelet receptor. 8 In the present study, we analysed whether this is a common characteristic of AIIAs or whether it is specific to certain AT 1 -receptor inhibitors.
Losartan dose-dependently reduced U46619induced platelet activation and attenuated the binding of TxA 2 to its human platelet receptor. This effect was also shown with lesser potency by valsartan. However, CV-11974, the active form of candesartan cilexetil, was ineffective.These results suggest for the first time that the antiplatelet effect of the AIIAs could be a differentiating property between them. The production of TxA 2 through the arachidonic acid pathway, acts directly to amplify platelet activation. 13 ADP stimulates the arachidonic acid pathway to increase production of TxA 2 which potentiates the activating effect of ADP on platelets. 13 ADP-induced platelet activation was 30% reduced by the cyclo-oxygenase inhibitor aspirin.This suggests that cyclo-oxygenase activity, mainly due to TxA 2 release, contributes about 30% to ADP-induced human platelet activation. Losartan also diminished ADP-mediated platelet activation by about 28%, an effect that was not potentiated by the presence of aspirin. However, the effect of the other AT 1 -receptor antagonists on ADP-induced platelet activation was potentiated by aspirin to the levels found with aspirin alone. These results may suggest that, although losartan had no effect on TxA 2 release (whereas aspirin inhibited TxA 2 release), it may inhibit ADP-induced platelet activation by a similar mechanism to aspirin.
The differential ability of the AIIAs to inhibit the TxA 2 /PGH 2 -receptors suggests that the structural requirements to antagonise the platelet TxA 2 /PGH 2 -receptor may be different from those involved in antagonism of the AT 1 -receptor.
One hypothesis for the mechanism of the antiplatelet effects is based on the importance of the hydroxilic radical contained in the imidazole ring of the AT 1 -receptor antagonists. Whereas losartan and valsartan both contain an imidazole ring, they differ one from the other in that valsartan contains a carboxilic radical whilst losartan possesses a hydroxylic radical.
Conversely, the active form of candesartan, CV-11974, which did not share the antiplatelet effects shown by the other two tested AIIAs, differs in structure. The chemical structure of CV-11974 shows a heterocycle moiety which hypothetically may confer inflexibility to its radicals, impairing its interaction with TxA 2 /PGH 2 -receptors. However, other chemical properties of the AIIAs, such as the net charge, pucker ability and hydrophilic and sterochemistry properties, could also be limiting factors in their interaction with TxA 2 /PGH 2 -receptors. Therefore, further studies beyond the scope of the present research are needed to elucidate the importance of the chemical properties of each specific AIIA to interact with TxA 2 /PGH 2receptors.
On the basis of the results presented, the concentration of losartan required to inhibit platelet aggregation (5x10 -7 mol/L) is high compared with plasma concentrations obtained in humans treated with losartan (approximately 5 x 10 -9 mol/L). The focus of the present study was only to analyse the direct effect of different AT 1 -receptor antagonists on platelets; thrombosis is a multicellular event in which other cells such as neutrophils and endothelium are involved in the regulation of platelet reactivity. 9, 10, 14, 15 In this regard, it has been postulated that acute in vivo administration of losartan increases levels of nitric oxide, a potent antiplatelet agent. 16 The concentration of losartan that may be needed to inhibit platelet activation in vivo may therefore be significantly lower than the concentration required in our in vitro study. The in vivo blockade of AT 1 -receptors may also exert antiplatelets properties beyond blockade of platelet TxA 2 /PGH 2 -receptors by some agents in the class for example, Ang II may favour the in vivo activation of platelets, not only through its vasoconstrictor properties but also by stimulating the production of plasminogen-activator inhibitor, 17 Both mechanisms are mainly dependent on AT 1receptor activation. 17, 18 In summary, the results of the present study demonstrated that losartan reduced TxA 2 -depen- dent platelet activation. Valsartan also showed an inhibitory effect on TxA 2 /PGH 2 -receptors in human platelets although only at high doses. This property was not shared by CV-11974, the active form of candesartan cilexetil. This feature could differentiate these AT 1 -receptor antagonists and may account for more beneficial cardiovascular effects.
